Clotilde Guidetti, MD

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Child Neuropsychiatry Unit, Department of Neuroscience, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy

JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Effect of Time From Onset of MDD on Response to Esmethadone
Original Research

May 13, 2024

Esmethadone 25 and 50 mg were more effective in reducing depression scale scores in patients who had a shorter time since their first major depressive episode.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe